DALLAS and TORONTO, Nov. 27, 2023 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) ("Perimeter" or the "Company") – a commercial-stage medical technology company – today announced that it will participate in an investor webinar hosted by PropThink Conferences featuring Dr. Amelia Tower, breast surgical oncologist, to discuss the re-excision epidemic and potential benefits of AI in cancer surgery. Following prepared remarks, investors will have an opportunity to ask relevant questions through an interactive Q&A portal.

Webinar Information:

Topic to include:

• the clinical need to fill the technology gap for surgeons needing to assess margin status in real time
• OCT imaging – a proven modality developed at MIT and used in other specialties for 30+ years – is being applied in a novel way in cancer surgeries
• an ultra-high resolution technology delivering 10x image resolution of X-ray and ultrasound and 100x greater than MRI
• how AI is integrated into the next generation of this device, currently in a clinical trial

The webcast link will also be posted on the Investors section of the Company's website, and archived following the event. The above listed dates and times are subject to change.

Other Resources Featuring Key Opinion Leaders:

For additional background, Perimeter's technology has been discussed by surgical key opinion leaders at previous industry conferences and events. Some highlights include:

• ASBrS Annual Meeting 2023 | Act in the Moment: OCT Adds Real-time Clarity on Margin Status
  Featuring Dr. Beth Anglin, Dr. Michele Carpenter and Dr. Beth DuPree (Moderator)
  
  
• SSO Annual Meeting 2023 | Managing Margins — Using OCT to Defend Against the Unknown
  Featuring Dr. Shawndeep Singh Tung and Dr. Nina Tamirisa
  
  
• ASBrS Annual Meeting 2022 | OCT + Future AI: Changing the Paradigm for Intraoperative Margin Visualization
  Featuring Dr. Richard E. Fine, Dr. Amelia Tower and Dr. Maryam Elmi

About Perimeter Medical Imaging AI, Inc.

Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSX-V: PINK) (OTC: PYNKF) (FSE: 4PC) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that is currently being evaluated in a pivotal clinical trial, with support from a grant of up to US$7.4 million awarded by the Cancer Prevention and Research Institute of Texas. The company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. In this news release, words such as "may," "would," "could," "will," "likely," "believe," "expect," "anticipate," "intend," "plan," "estimate," and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management's future outlook and anticipated events or results and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Without limitation, information regarding the potential benefits of Perimeter S-Series OCT and Perimeter B-Series OCT, the expected benefits of Perimeter's updated version of its ImgAssist AI, and the expected details regarding Perimeter's ongoing clinical trials, are forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, any particular result will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions, and other unpredictable factors, many of which are beyond Perimeter's control. Such forward-looking statements reflect Perimeter's current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter's financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described in Perimeter's Management Discussion and Analysis for the year ended December 31, 2022, which is available on Perimeter's SEDAR+ profile at https://www.sedarplus.ca, and could cause actual events or results to differ materially from those projected in any forward-looking statements. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws.